Clearmind Medicine Inc. (NASDAQ: CMND), an Israeli biotech company received approval from the IMCA center’s Ethics Committee for the announced Phase 1/2 clinical trial assessing its proprietary MEAI-based compound, CMND-100, for the treatment of Alcohol Use Disorder (AUD.) Clearmind discovers and develops novel psychedelic-derived therapeutics for major undertreated health problems.

The Ethics Committee -the European and Israeli equivalent of the IRB in the U.S.- of the IMCA center, operating under the Declaration of Helsinki regulations and other international conventions around medical experiments on humans, must authorize, review and monitor medical research and trials involving human subjects. 

The committee reviews research protocols and related materials (such as informed consent documents and investigator …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.